从11%到17%：国产液质的“场景争夺战”才刚刚打响！

Core Insights - The article emphasizes the transition of China's mass spectrometry industry from merely producing equipment to exploring significant application opportunities, particularly in the context of increasing domestic market share in LC-MS systems, which is projected to rise from approximately 11% in 2024 to 17% in 2025 [1][2]. Group 1: Market Dynamics - The dominance of imported brands in the LC-MS market has been challenged by the increasing market share of domestic products, indicating a shift towards targeted applications rather than broad-based competition [1]. - The article highlights the necessity for mass spectrometry companies to evolve from general-purpose machines to specialized solutions tailored for specific high-demand applications to enhance profitability [1][2]. Group 2: Key Highlights from the Forum - The upcoming "ACCSI 2026" forum will focus on three major growth areas: clinical medical applications, frontiers in omics, and environmental pollution management, featuring insights from industry leaders [2][3]. - The forum will include discussions on the real needs for mass spectrometry in clinical settings, particularly regarding compliance and project implementation challenges [2][4]. - A competitive segment will feature both domestic and international companies discussing practical business pathways rather than just technical specifications, aiming to address real-world challenges in the industry [4][5]. Group 3: Ecosystem Development - The importance of ecosystem development alongside hardware innovation is underscored, with discussions on optimizing operational efficiency and talent cultivation within the mass spectrometry field [5][6]. - The forum will also unveil new domestic mass spectrometry products, showcasing advancements in Chinese manufacturing capabilities [5][6].